References
- Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–2393.
- Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271–1277.
- Ziakas PD, Poulou LS, Giannouli S, et al. Thrombocytopenia in lupus: baseline C3 as an independent risk factor for relapse. Ann Rheum Dis. 2007;66(1):130–131.
- Lurie DP, Kahaleh MB. Pulse corticosteroid therapy for refractory thrombocytopenia in systemic lupus erythematosus. J Rheumatol. 1982;9(2):311–314.
- Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–186.
- Serris A, Amoura Z, Canouï-Poitrine F, et al. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: a multicenter retrospective cohort study of 71 adults. Am J Hematol. 2018;93(3):424–429.
- Jovancevic B, Lindholm C, Pullerits R. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature. Lupus. 2013;22(7):664–674.
- Alarcon-Segovia D. Splenectomy has a limited role in the management of lupus with. J Rheumatol. 2002;29(1):1–2.
- Maier WP, Gordon DS, Howard RF, et al. Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia. Arthritis Rheum. 2010;33(8):1233–1239.
- Ter Borg EJ, Kallenberg CG. Treatment of severe thrombocytopenia in systemic lupus erythematosus with intravenous gammaglobulin. Ann Rheum Dis. 1992;51(10):1149–1151.
- Rivero SJ, Alger M, Alarcón-Segovia D. Splenectomy for hemocytopenia in systemic lupus erythematosus: a controlled appraisal. Arch Intern Med. 1979;139(7):773–776.
- Eber SW, Langendörfer CM, Ditzig M, et al. Frequency of very late fatal sepsis after splenectomy for hereditary spherocytosis: impact of insufficient antibody response to pneumococcal infection. Ann Hematol. 1999;78(11):524–528.
- Anstead GM. Steroids, retinoids, and wound healing. Adv Wound Care. 1998;11(6):277–285.
- Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989;11(6):954.
- Bollet AJ, Black R, Bunim JJ. Major undesirable side-effects resulting from prednisolone and prednisone. JAMA. 1955;158(6):459.
- Khellaf M, Chabrol A, Mahevas M, et al. Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies. Am J Hematol. 2014;89(2):194–198.
- Tanaka Y. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases. Intern Med. 2007;46(16):1313–1315.
- Brah S, Chiche L, Fanciullino R, et al. Efficacy of rituximab in immune thrombocytopenic purpura: a retrospective survey. Ann Hematol. 2012;91(2):279–285.
- Lindholm C, Börjesson-Asp K, Zendjanchi K, et al. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol. 2008;35(5):826–833.
- Boumpas DT, Barez S, Klippel JH, et al. Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus. Ann Intern Med. 1990;112(9):674–677.
- Vasoo S, Thumboo J, Fong KY. Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil. Lupus. 2003;12(8):630–632.
- Quartuccio L, Sacco S, Franzolini N, et al. Efficacy of cyclosporin-A in the long-term management of thrombocytopenia associated with systemic lupus erythematosus. Lupus. 2006;15(2):76–79.
- Quartuccio L, Sacco S, Franzolini N, et al. Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus. Lupus. 2015;24:746–750.